Circadian OS is pioneering circadian therapeutics—a new class of medicine that measures and reprograms the body’s internal clock to improve how time-sensitive treatments work. The company integrates a proprietary blood test with software-driven, personalized light dosing delivered through everyday devices such as iPads. This dual approach restores immune readiness and aligns peak immune activity with drug administration, amplifying the efficacy of therapies like cancer immunotherapy without adding toxicity.

Originating from Nobel Prize–winning circadian biology at Rockefeller University with co-founders Sofia Axelrod (PhD, Rockefeller), Alexandra Saali (MD, Mount Sinai), and Thomas Brennan (PhD, ARCH Venture Partners), Circadian OS is backed by early human data and partnerships with Mount Sinai, Roche, and Cornell.